Vivos Therapeutics

Rising Debt And Regulatory Risks Will Limit Healthcare Expansion

AnalystLowTarget

Not Invested

Consensus Narrative from 2 Analysts

Published

18 Aug 25

Updated

28 Aug 25

AnalystLowTarget's Fair Value

US$4.00

13.3% overvalued

28 Aug

US$4.53

75.6%

-1.4%

75.6%

-1.4%

Edit anytime before Aug 18 10:10 PM. Then post Updates to your followers.

Author's Valuation

US$4.0

13.3% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$4.0

13.3% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

36.04%

Healthcare Services revenue growth rate

0.24%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$3.12m

Earnings '28

25.71x

PE Ratio '28

US$80.29m

Market Cap '28

US$80.29m

Market Cap '28

16.49m

No. shares '28

US$4.87

Share Price '28

US$4.87 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$4.00

Fair Value '25